Oral Glibenclamide in Premature Hyperglycaemia (GALOP)
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm hypothesis that Glibenclamide can be administered
orally and is an alternative to insulin therapy in treating transient hyperglycemia of
premature newborns.